By this, consolidation chemotherapy consisting of dexamethasone, vincristine, and doxorubicin, followed by cyclophosphamide, Ara‐C, and 6‐thioguanine is given in patients with ALL [2], while patients with AML are consolidated with intermediate or high doses of cytarabine (HDAC) and Fms-like Tyrosine Kinase 3 (FLT3)-inhibitors in patients with FLT3-mutations [3]. The gene discussed is FLT3; the disease is acute myeloid leukemia.